title: Glutamate metabolism and HIV-associated neurocognitive disorders.
abstract: HIV-1 infection can lead to neurocognitive impairment collectively known as HIV-associated neurocognitive disorders (HAND). Although combined antiretroviral treatment (cART) has significantly ameliorated HIV's morbidity and mortality, persistent neuroinflammation and neurocognitive dysfunction continue. This review focuses on the current clinical and molecular evidence of the viral and host factors that influence glutamate-mediated neurotoxicity and neuropathogenesis as an important underlying mechanism during the course of HAND development. In addition, discusses potential pharmacological strategies targeting the glutamatergic system that may help prevent and improve neurological outcomes in HIV-1-infected subjects.
authors.affiliation: Department of Microbiology, Ponce School of Medicine and Health Sciences, Ponce, 00716, Puerto Rico.
authors.forename: Fabián J
authors.initials: FJ
authors.lastname: Vázquez-Santiago
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Noel
authors.forename: James T
authors.initials: JT
authors.lastname: Porter
authors.forename: Vanessa
authors.initials: V
authors.lastname: Rivera-Amill
mesh_terms: D015526:AIDS Dementia Complex / Q000378:metabolism*; D000818:Animals; D018698:Glutamic Acid / Q000378:metabolism*; D015497:HIV-1; D006801:Humans
chemical_list: D018698:Glutamic Acid